CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Regeneron Pharmaceuticals Incorporated Company Snapshot
Regeneron Pharmaceuticals Incorporated operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Regeneron Pharmaceuticals Incorporated with three other companies in this sector in UNITED STATES : Zoetis Inc (2020 sales of $6.68 billion of which 53% was US), Vertex Pharmaceuticals Inc ($6.21 billion of which 62% was TRIKAFTA), and Alexion Pharmaceuticals, Inc. ($6.07 billion of which 67% was Soliris).

Sales Analysis. Sales were up sharply during the second quarter of 2021 versus the previous year's second quarter. During the second quarter of 2021, sales at Regeneron Pharmaceuticals Incorporated totalled $5.14 billion. This is an increase of 163.2% from the $1.95 billion in sales at the company during the second quarter of 2020. This was the biggest same quarter rise in sales at Regeneron Pharmaceuticals Incorporated in the previous 35 quarters. During the first two quarters of 2021, sales totalled $7.67 billion, which is 102.8% higher than through the first two quarters of 2020. During the previous 34 quarters, sales at Regeneron Pharmaceuticals Incorporated have increased compared with the same quarter in the previous year. Regeneron Pharmaceuticals Incorporated reported sales of $8.50 billion for the year ending December of 2020. This represents an increase of 8.1% versus 2019, when the company's sales were $7.86 billion. Sales at Regeneron Pharmaceuticals Incorporated have increased during each of the previous five years (and since 2015, sales have increased a total of 107%). Sales of Libtayo saw an increase that was more than double the company's growth rate: sales were up 54.1% in 2020, from $175.70 million to $270.70 million. Regeneron Pharmaceuticals Incorporated also saw significant increases in sales in Other Revenues (up 34.7% to $557.00 million) . Not all segments of Regeneron Pharmaceuticals Incorporated experienced an increase in sales in 2020: sales of Sanofi fell 16.8% to $1.19 billion. Regeneron Pharmaceuticals Incorporated also experienced decreases in sales in Bayer (down 0.2% to $1.19 billion) and Arcalyst (down 9.7% to $13.10 million) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Regeneron Pharmaceuticals Incorporated
  Stock Performance Chart for Regeneron Pharmaceuticals Incorporated
 
  Stock Data: Recent Stock Performance:
  Current Price (10/15/2021): 553.24
(Figures in U.S. Dollars)
1 Week 0.6%   13 Weeks -15.1%  
4 Weeks -5.1%   52 Weeks -7.8%  
 
Regeneron Pharmaceuticals Incorporated Key Data:
  Ticker: REGN Country: United States
  Exchanges: NAS Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2020 Sales 8,497,100,000
(Year Ending Jan 2021).
Employees: 9,123
  Currency: U.S. Dollars Market Cap: 59,041,676,536
  Fiscal Yr Ends: December Shares Outstanding: 106,719,826
  Share Type: Common Closely Held Shares: 4,741,887
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.